1 **Title**

2 A routine method for cloning, expressing and purifying A β (1-42) for structural NMR studies

3

4 **Authors**

5 1. Daniel K. Weber^a,

6 2. Marc-Antoine Sani^a,

7 3. John D. Gehman^{a,b} (Corresponding Author)

8 ^a School of Chemistry, Bio21 Institute, University of Melbourne, Victoria, Australia

9 ^b GehmanLab, Woodend, Victoria, Australia (current address)

10 Corresponding Author: John D Gehman jgehman@gehmanlab.com +61 407 536 585

Abstract

Nuclear magnetic resonance (NMR) is a key technology in the biophysicist's toolbox for gaining atomic-level insight into structure and dynamics of biomolecules. Investigation of the amyloid- β peptide ($A\beta$) of Alzheimer's Disease is one area where NMR has proven useful, and holds even more potential. A barrier to realizing this potential, however, is the expense of the isotopically enriched peptide required for most NMR work. Whereas most biomolecular NMR studies employ biosynthetic methods as a very cost-effective means to obtain isotopically enriched biomolecules, this approach has proven less than straightforward for $A\beta$. Furthermore, the notorious propensity of $A\beta$ to aggregate during purification and handling reduces yields and increases the already relatively high costs of solid phase synthesis methods. Here we report our biosynthetic and purification developments that yield pure, uniformly enriched ^{15}N and $^{13}\text{C}^{15}\text{N}$ $A\beta(1-42)$, in excess of 10 mg/L of culture media. The final HPLC-purified product was stable for long periods, which we characterize by solution-state NMR, thioflavin-T assays, circular dichroism, electrospray mass spectrometry, and dynamic light scattering. These developments should facilitate further investigations into Alzheimer's Disease, and perhaps misfolding diseases in general.

Key words

Recombinant peptide, uniform labeling, amyloid beta peptide, Alzheimer's disease, protein NMR, SUMO, thioflavin T assay, circular dichroism.

31 **Abbreviations**

32 A β amyloid beta peptide; APP, amyloid precursor protein; CD, circular dichroism; CV,
33 column volume; DLS, dynamic light scattering; ESI-MS, electrospray ionization mass
34 spectrometry; Gdm.HCl, guanidine hydrochloride; GFP, green fluorescent protein; HSQC,
35 heteronuclear single quantum coherence; IPTG, isopropyl β -D-1-thiogalactopyranoside; LB,
36 lysogeny broth; LC-MS, liquid chromatography-mass spectrometry; MAP, methionine
37 aminopeptidase; NMR, nuclear magnetic resonance; Ni-NTA, nickel-nitrilotriacetic acid; PTM,
38 post-translational modification; ROS, reactive oxygen species; RP-HPLC, reverse-phase
39 high-performance liquid chromatography; RT, room temperature; SPPS, solid phase peptide
40 synthesis; SUMO, small ubiquitin-like modifier; TB, terrific broth; TEV, Tobacco Etch Virus
41 protease; and Ub, ubiquitin.

Introduction

Extracellular neuronal deposits predominantly composed of insoluble fibrillar structures of amyloid beta peptides are ubiquitous in Alzheimer's disease (AD) pathology. These peptides, varying from 39 to 43 residues in length, originate from proteolytic processing of the amyloid precursor protein (APP) (1), whereby production biased towards the highly amyloidogenic 42-residue isoform A β (1-42) is a significant risk factor towards the onset of AD (2). Mechanistic links of A β peptides to neurodegenerative symptoms, however, have been challenging to identify, but are often proposed in relation to metal binding (3), catalytic roles in reactive oxygen species (ROS) generation (4-6) and perturbing interactions towards model lipid membranes (7-11).

Structural data obtained from nuclear magnetic resonance (NMR) has helped to better understand the pathogenicity of A β peptides and to inform rational drug design efforts. NMR-based structural models include helical structures in membrane-mimetic solvents or micelles (12-16), predominately unstructured monomers under aqueous conditions at low temperatures (17, 18), and insoluble fibrillar structures rich in beta sheet (19-23). In addition to overcoming the limitations of X-ray diffraction imposed by the non-crystalline and highly polymorphic nature of A β peptides, NMR also provides additional information on dynamics, which could be used in conjunction with computational methods to better appreciate the conformational space populated by the peptide in its native, intrinsically disordered state (24-26). Such studies are, however, limited to the availability of an inexpensive source of milligram quantities of peptide, uniformly or selectively labeled with NMR-useful isotopes (i.e. ^{13}C , ^{15}N , ^2H , ^{19}F , etc.).

The large quantities of protein needed for structural biology is typically supplied reasonably efficiently by biosynthesis in *E. coli* or other expression systems. The need for ^{15}N and ^{13}C isotopically enriched molecules in NMR involves simple refinement of the growth media to supply only ^{15}N - and/or ^{13}C -enriched metabolic precursors as the sole nitrogen and carbon sources, respectively. Biosynthetic expression of peptides, however, is not quite as

straightforward, and solid phase peptide synthesis is more commonly employed to produce peptide by means of synthetic chemistry. Where just a few nuclei within a peptide are to be labelled, solid phase synthesis is still standard, albeit with increased cost owing to such specialized precursors (27). Uniform labelling of peptide, however, quickly becomes cost-prohibitive by solid phase synthesis. For the A β peptide, these problems are particularly acute, given the 40-42 residue length of the peptide, as well as the poor yields of pure, unmodified, and unoxidized material through for which it is infamous (revised by Finder *et al.* (28).

Toward overcoming such limitations, mixed success has been reported with adapting for peptides the fusion-protein approach sometimes applied to problematic proteins. In this approach, recombinant DNA techniques are used to create a fusion protein where a well-behaved protein subunit is both affinity-tagged for purification ease and linked to a protein of interest with a peptide linker plus protease cleavage site, such as for TEV, Factor Xa, or enterokinase. A β (1-40) and A β (1-42) free of extraneous N-terminal methionine (as is often the case for straight biosynthesis in *E. coli*) or other residues from sloppy protease cleavage has indeed been produced by this approach (28-31). Adaptations of these methods for isotope labeling, however, have only been comprehensively described for the less-amyloidogenic (and less disease-relevant) A β (1-40), either providing low (<2 mg/L of culture) or undisclosed final yields (31). This may in part be due to the typical losses in yield owing to the use of specialized minimal growth media compared to high-density media for routine biosynthetic protein production at natural isotopic abundance (30).

In this study we provide a significantly improved protocol for producing entirely native, uniformly ^{15}N and $^{13}\text{C}^{15}\text{N}$ labeled recombinant A β (1-42) at yields exceeding 10 mg per liter of culture. A scheme based on a SUMO fusion partner is utilized, which has demonstrated promising results for expressing A β (1-42), albeit only from small scale cultures (32). The potency, reliability and stability of SUMO protease (Ulp1) compared to traditional-used proteases, which are selective to degenerate linkers and required in prohibitive quantities, also provides significant advantages (33). Furthermore, we incorporate several attractive

features including a modular cloning approach for flexibility in producing mutants or other isoforms of A β (34), a fast and simple workflow for isolation and purification of amyloid beta from cleavage reactions (28) and a once-off preparation of SUMO-protease (35) sufficient for routine preparative-scale implementation. The chemical and conformational state of the final product is evaluated by electrospray ionization mass spectrometry, solution NMR, thioflavin T assay and circular dichroism techniques.

Materials and Methods

Cloning, expression and purification of SUMO-A β (1-42)

The A β (1-42) gene was synthesized by PCR according to the codon-optimized sequence and modular approach previously described by Walsh *et al.* (34). Taq DNA polymerase (MyTaq Red Mix, Bioline, Australia) and oligonucleotides, modified for compatibility with 3' overhangs introduced by Taq, sA β , 5' - GACGCTGAATTCCGTCACGACTCTGGTTACGAAGTTCACCACCAGA - 3'; sA β , 5' - CACCACCAGAAGCTGGTGTCTTCGCTGAAGACGTGGGTTCTAACAAGGGTGCT-3'; aA β , 5' - TTACACAACGCCACCAACCATCAGACCGATGATAGCACCTTGTTAGA - 3'; aA β 42d, 5' - TTAAGCGATCACAACGCCACCAACCATCAGACCGAT - 3'; sA β wd, 5' - CAGGTCTCAAGGTGACGCTGAATTCCGTCAC - 3'; and aA β 42rev, 5' - CAGGTCTCTCTAGATTTAAGCGATCACAACGCC - 3' (Micromon, Australia) were used to construct the gene (see Fig. 1) with BsaI and XbaI restriction sites for subsequent cloning into a pE-SUMOpro expression vector (T7, ampicillin; LifeSensors, Malvern, PA, USA). The construct, encoding a 6-His-tagged SUMO fused to the N-terminus of A β (1-42), was propagated using *E. coli* DH5 α subcloning cells (Invitrogen) and verified by colony PCR and DNA sequencing (Applied Genetic Diagnostics, University of Melbourne, Australia).

For expression of unlabeled (natural abundance) SUMO-A β (1-42), a single colony of freshly transformed *E. coli* One Shot BL21(DE3) expression cells (Invitrogen), selected from a LB agar plate (including 100 μ g/mL ampicillin), were used to inoculate LB-Miller overnight

124 starter-cultures. Day cultures of 500 mL LB-Miller (including 100 µg/mL ampicillin) were then
125 inoculated from 5 mL of starter-culture (OD_{600} 1.5) and grown at 37°C with 275 RPM shaking.
126 Cells were induced with 1 mM IPTG once the OD_{600} reached 0.6 (~3.5 hrs). Growth continued
127 for 4 hrs (OD_{600} 1.4) before cells were harvested by centrifugation (8000 g, 10 min, 4°C).
128 Pellets were snap-frozen with N₂ (l) and stored at -20°C (3.1 g/L culture wet cell mass).

129 Uniformly labeled ¹⁵N and ¹³C¹⁵N SUMO-Aβ(1-42) were expressed from cultures grown
130 in Neidhardt's minimal media (36), with 0.52 g/L ¹⁵NH₄Cl and 5.2 g/L [U-¹³C]-glucose
131 (Cambridge Isotope Laboratories) being the sole nitrogen and carbon sources, respectively.
132 The culture media (including 100 µg/mL ampicillin) were freshly prepared using the method
133 described by Gehman *et al.* (2008) (37), and sterile-filtered immediately prior to use. Cultures
134 expressing ¹⁵N SUMO-Aβ(1-42) were grown as described above for natural-abundance
135 cultures and harvested 4 to 5 hours post-induction (OD_{600} 1.1), yielding wet cell masses of 3.0
136 g/L of culture. For expression of ¹³C¹⁵N SUMO-Aβ(1-42), cells were initially grown in ¹⁵N-
137 enriched media with natural abundance glucose and centrifuged (8000 g, 10 min, 4°C) once
138 the OD_{600} reached 0.6. Pellets were resuspended in fresh ¹³C¹⁵N-enriched media, induced at
139 an OD_{600} 0.8, then harvested 4 to 5 hours after induction (OD_{600} 2.1) to yield a wet cell mass
140 of 5.5 g/L of culture.

141 Hexahistidine-tagged SUMO-Aβ(1-42), as reported in pilot-scale work by Satakarni
142 and Curtis (32), was found to accumulate in inclusion bodies when expressed in *E. coli*.
143 Accordingly, frozen cell pellets were suspended into denaturing lysis buffer (6 M Gdm.HCl,
144 100 mM sodium phosphate, 10 mM tris, pH 8.0; 10 mL per 1 g wet cell mass) and sonified on
145 ice to aid lysis (Branson 250; 50% duty cycle, level 5 output). The crude lysate was stirred on
146 ice for 1 hr then clarified by centrifugation (10 000 g, 30 min, RT). The supernatant was
147 applied to a Ni-NTA agarose resin (Qiagen; 10 mL bed volume per 1.3 g of wet cell mass)
148 and then washed with 10 column volumes (CVs) of denaturing buffer (8 M urea, 100 mM
149 sodium phosphate, 10 mM tris, pH 8.0). The fusion protein was refolded on the resin by
150 exchange into 100% native buffer (50 mM sodium phosphate, 300 mM NaCl, pH 8.0) over 4
151 CVs, increasing concentration stepwise at 25%/CV from denaturing buffer, then washing with

a further 10 CVs of 100% native buffer. Elution took place over 4 CVs of elution buffer (50 mM sodium phosphate, 300 mM NaCl, 250 mM imidazole, pH 8.0) and the protein stored at 4°C. All purification steps with urea were done using chilled buffers as a precaution against possible carbamylation modifications. Purities of 60-90% were determined from SDS-PAGE. Higher purity (>90%) could be obtained using wash buffers at pH 6.3 (denaturing) or containing 20 mM imidazole (native), but not without significant losses from premature elution of protein. Accounting for impurities, final yields of unlabeled, ¹⁵N and ¹⁵N¹³C SUMO-Aβ(1-42) were 96, 96 and 181 mg/L of culture, respectively, as determined by Bradford assay (38) using Bovine serum albumin (Sigma) as a standard.

Cleavage and purification of Aβ(1-42)

SUMO-Aβ(1-42) (~100 μM), freshly eluted from Ni-NTA resin, with 2 mM DTT added, was cleaved by Ulp1 (preparation described below), at 1000:1 substrate to enzyme molar ratio, for 1-3 days at 4°C. Aggregation was induced by carefully lowering the pH to between 6.5 and 7.0 with 1 M HCl and subsequent incubation at 37°C for 3 hours. Aβ(1-42) was then pelleted by centrifugation (10 000 g, 15 min, RT) and dissolved into 8 M Gdm.HCl or 70% formic acid (~5 mg/mL peptide). Aβ(1-42) was purified by HPLC using a preparative Phenomenex Jupiter C4 column (150 x 21.2 mm, 10 μm particle size, 300 Å pore), maintained at 60°C using a Phenomenex Thermosphere TS-430 column heater. Sample was injected at a 2 mL/min flow rate of TFA (0.1%) and acetonitrile (10%) over 5 minutes, and eluted at 10 mL/min flow using a 20 to 90% linear gradient of acetonitrile over 30 min. Elution volumes were lyophilized and stored at -20°C. Yields of lyophilized unlabeled, ¹⁵N and ¹³C¹⁵N Aβ(1-42) were 13, 12, and 22 mg/L of culture, respectively, equating to ~40% of the yield expected from quantities of SUMO-Aβ(1-42) purified from cell masses.

Cloning, expression and purification of SUMO protease

DNA encoding residues 403 to 621 of *Saccharomyces cerevisiae* Ulp1 (SUMO Protease 1), with a hexahistidine tag on both the N and C termini (35), was obtained by gene synthesis

(GeneArt, Invitrogen) and codon-optimized using the GeneOptimizer tool supplied. The gene was subsequently cloned into a pET21a(+) expression vector (Novagen) using NdeI and XhoI restriction sites on the N and C terminus, respectively, and propagated using *E. coli* DH5α subcloning cells (Invitrogen).

For expression, sequence-verified plasmid (Applied Genetic Diagnostics, University of Melbourne, Australia) was freshly transformed into *E. coli* One Shot BL21(DE3) expression cells (Invitrogen). Cells were grown in LB-Miller media (including 100 g/mL ampicillin) at 37°C with 275 RPM shaking. Expression was induced with 1 mM IPTG once OD₆₀₀ reached 0.6, and growth continued for a further 4 hr (OD₆₀₀ 1.8). Cells were harvested by centrifugation (8000 g, 10 min, 4°C), frozen with N₂ (l) and stored at -20°C (5.9 g/L of culture wet cell mass).

For purification, frozen cell pellets were resuspended into native buffer (50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole, 2 mM DTT, pH 8.0) and lysed by sonification (Branson 250, 50% duty cycle, level 5 output), on ice, with 15 cycles of 30 s bursting and 30 s cooling periods. The lysate was clarified by centrifugation (10 000 g, 15 min, 4 °C), and the supernatant loaded onto Ni-NTA resin (Qiagen). The resin was washed with 10 column volumes (CVs) of native buffer containing 20 mM imidazole and eluted with 350 mM imidazole. Fractions with Ulp1 were pooled, diluted 2-fold with 100% glycerol and stored at -20 °C. The product was confirmed by LC-MS (SGE ProteCol C18, 150.0 x 2.0 mm, 5 µm particle size, 120 Å pore) using a formic acid (0.1%) flow rate of 0.25 mL/min and a linear gradient of 5 to 90% MeCN over 10 min. The average mass was 27 250.24 Da (27 249.96 amu theoretical). Yields of 60 mg/L of culture were determined using a theoretical extinction coefficient at 280 nm (28 590 M⁻¹ cm⁻¹).

Mass spectrometry

All mass spectrometry was done using an Agilent TOF 6220 equipped with a dual spray electrospray ionization source. Data were recorded between 100 and 3200 m/z, in positive-

ion mode with 4000 V capillary voltage, 250 V fragmentor voltage for protein samples (or 200 V for peptide), 65 V skimmer voltage, 250 V octopole voltage, 35 psi nebulizer pressure, and 7.0 L/min N₂ drying gas flow at 325 °C. All spectra were analyzed using Agilent MassHunter Qualitative Analysis Software (Version B.05.00, Build 5.0.519.0).

NMR spectroscopy

Lyophilized recombinant A β (1-42), between 1 and 2 mg, was dissolved into 500 μ L of 10% NH₃ with vortexing and 5 mins bath-sonication, then lyophilized. The peptide was re-dissolved into 60 μ L of 50 mM NaOH and then made to 600 μ L to consist of buffer (15 mM sodium phosphate, 55 mM NaCl, pH 7.4) and 10% D₂O. The pH was carefully corrected to 7.4 (and not adjusted for pD) by addition of HCl and centrifuged (22000 g, 10 min, 4°C) to remove any aggregated material. The concentration of the supernatant was checked by absorbance at 214 nm using a theoretical coefficient (39) of 76 848 M⁻¹ cm⁻¹, and the sample loaded into an ice-cold NMR tube. Sample concentrations typically varied between 200 to 600 μ M.

NMR spectra were acquired using a cryoprobe-equipped Bruker 500 MHz Avance II spectrometer. Measurements were made at 5°C, in which the sample could remain soluble for over one week without any visible aggregation or detectable loss in signal. Full backbone chemical shift assignments were made using ¹⁵N-HSQC, HNCOC and HNCACB spectra. The ¹H dimensions were referenced directly to trimethylsilyl propionate-d₄ (TSP-d₄) at -0.12 ppm and ¹⁵N and ¹³C frequencies indirectly by their gyromagnetic ratios (40). Spectra were processed with NMRPipe (41) and analyzed using CCPNmr Analysis (42).

Thioflavin T aggregation assays

Aggregate-free NMR samples were prepared by dissolving lyophilized synthetic (W. M. Keck Facility, Yale University, New Haven, CT) or recombinant A β (1-42) into 10% NH₃ at ~1 mg/mL with vortexing and 5 mins bath-sonication. The peptide was then lyophilized and re-dissolved into 5 mM NaOH at ~100 μ M then centrifuged (22000 g, 10 min, 4 °C) to remove

any remaining aggregates. The supernatant was then checked by absorbance at 214 nm using and experimentally determined extinction coefficient of $89\,665\text{ M}^{-1}\text{cm}^{-1}$ for synthetic peptide and a theoretical coefficient for recombinant peptide of $76\,848\text{ M}^{-1}\text{cm}^{-1}$, noting that synthetic preparations have been described to have impurities that lead ~20% overestimations of concentration using theoretical coefficients (28). Stocks of A β (1-42) were then made to 40 μM in buffer (30 mM sodium phosphate, 100 mM NaCl, pH 7.4) and kept on ice prior to measurements.

Aggregation assays were performed using black, clear-bottom, 96-well plates (Greiner, Fluotrac 600). Wells were prepared to a total volume of 200 μL and comprised of 10 μM A β (1-42) and 20 μM thioflavin T (ThT, Sigma-Aldrich, St Louis, MO) in buffer. Measurements were made at 37°C using a FLUOstar Optima plate reader with 440 nm and 480 nm excitation and emission filters, respectively. Wells were scanned by bottom-read every 10 mins with 5 s shaking prior to measurements.

Circular dichroism

Circular dichroism (CD) measurements were made using a Chirascan-Plus (Applied Photophysics) spectrometer and recorded in triplicate from 185 – 260 nm with 1 nm step size, 1 nm bandwidth, 1 s time-per-point and 0.1 mm path-length cuvettes. Temperature was incremented stepwise from 5°C to 50°C, with 5 min equilibration time prior to each scan.

Results

Cloning, expression and purification of SUMO-A β (1-42)

The A β (1-42) gene was synthesized by an adaptation of the PCR-based modular approach described by Walsh *et al.* (34). The protocol required only six oligonucleotides, in which mutations, if desired, can be made by a simple substitution of oligonucleotide components. Adaptions were made to add the required BsaI and XbaI restriction sites for subsequent insertion into the commercial SUMO expression system used, and the oligonucleotide

sequences modified for compatibility with the adenine overhang introduced by Taq DNA polymerase, which, theoretically, also allows direct use of expression systems based upon TA cloning.

SUMO-A β (1-42) was expressed from *E. coli* BL21(DE3) cells under control of the T7/lac promoter system, grown from either LB media for natural isotopic abundance, or Neidhardt's minimal media for uniform ^{15}N and ^{13}C labeling. Yields of fusion protein were high (96 mg/L of culture) regardless of culture medium, although an obvious reduction in growth rate was observed for Neidhardt's medium (Fig. 2A). Furthermore, [U- ^{13}C]-glucose requirements for $^{13}\text{C}^{15}\text{N}$ SUMO-A β (1-42) were essentially halved by growing cell mass to mid log phase at natural abundance carbon (with ^{15}N -enrichment), followed by resuspension and induction under fully ^{13}C - and ^{15}N -labeled growth conditions, which yielded 181 mg of fusion protein per liter of the final culture.

As prior work has determined that this particular fusion accumulates primarily into inclusion bodies (32), lysis and initial purification steps were done using denaturing buffers. SUMO-A β (1-42) was simply isolated by Ni-NTA affinity chromatography on the basis of an N-terminal hexahistidine tag, whereby the use chilled buffers was sufficient for averting risks of carbamylation modifications from urea degradation (43). Furthermore, refolding of the fusion protein was achieved rapidly by on-resin exchange into native buffer, with no loss in yield, purity or cleavage efficiency compared with refolding through 3 days of dialysis (data not shown).

ESI-LCMS revealed the average mass of SUMO-A β (1-42) to be 16775 Da (Fig. 2B), exactly 131 Da less than expected and corresponds to the loss of the N-terminal methionine residue, most likely from post-translational modification (PTM) by methionine aminopeptidase (MAP) (44). Average masses for ^{15}N and $^{15}\text{N}^{13}\text{C}$ SUMO-A β (1-42) were measured at 16985 Da and 17691 Da, respectively. Enrichment of ^{15}N was therefore determined to be 99%, and ^{13}C -enrichment of doubly labeled protein was 97% based on the assumption of 99% ^{15}N -enrichment. SDS-PAGE analysis of expressed and purified fusion protein (Fig. 2C) shows the fusion protein to migrate as multiple bands. The apparent molecular weight and intensity

of these extra bands (generally greater for isotope-enriched batches) corresponds well with additional peaks at +178 Da and +258 Da extra mass from ESI-MS spectra (Fig. 2B) and are consistent with addition of α -N-6-phosphogluconoyl (+258 Da) with subsequent dephosphorylation to α -N-gluconoyl (+178 Da), which is a common N-terminal PTM for his-tagged fusion proteins (45). Furthermore, the extra masses were identical between natural abundance and ^{15}N -enriched protein, as expected from being a nitrogen-free PTM, while ^{13}C -enrichment of doubly labeled material increased the observable +178 Da mass to +183 Da – roughly consistent (at least within error of mass determination) with six additional ^{13}C atoms.

Cleavage and Purification of A β (1-42)

The active unit of SUMO protease 1 (Ulp1) is defined as the amount required to cleave 15 μg of SUMO-M-GFP at 25 °C in 1 hr (33). Accounting for the molar mass of SUMO-A β (1-42), a standard reaction with 100 mg of fusion protein would require almost 15000 units of enzyme. Enzyme requirements for routine production of A β (1-42) would, therefore, be cost prohibitive with current commercial sources. For this reason, we cloned and expressed a dual-his-tagged catalytic Ulp1(403-621) domain from *Saccharomyces cerevisiae* as reported by Lee *et al.* (35). Expression from *E. coli* BL21(DE3) provided approximately 60 mg of enzyme per liter of culture, in which a single one liter batch provided sufficient enzyme to cleave over 35 g of SUMO-A β (1-42) using the protocol described within this paper.

Cleavage of SUMO-A β (1-42) was performed at 4°C to reduce risks of A β (1-42) aggregation throughout the reaction. Figure 2D shows that an enzyme to substrate molar ratio of 1:10 was sufficient for approximately 75% cleavage over 1 hour at 4°C, which is several orders of magnitude slower than previous reports of complete cleavage at ratios as low as 1:10000 (33). While 4°C is much lower than optimal range of 22 to 37°C, enzyme activity was only expected to be reduced by approximately a factor of two (33). Soluble aggregates, however, were observed and roughly estimated by DLS to have a hydrodynamic radius of 12 nm, with intensity also centered around 200 nm arising from a small population a larger aggregates considering the sixth-power relationship of light scattering intensity to

particle size (Fig. 2E). Therefore, obstruction of the cleavage site may explain the observed enzymatic inefficiencies. Nonetheless, losses in activity were compensated for by an extended cleavage duration, in which periods longer than 24 hours were sufficient for maximal cleavage (~75 %) at a ratio of 1:1000 (Fig. 2C). The tolerance of Ulp1 against high salt and imidazole content allowed cleavage to be done immediately following elution from Ni-NTA resin, i.e. without any need of buffer exchange or pH adjustment. Cleavage at ~100 μ M fusion protein occurred without any visible aggregation of liberated A β (1-42), even upon heating to 37°C. Subsequent pH-adjustment from 8.0 to between 6.5 and 7.0, with incubation at 37°C for several hours, was required for complete aggregation, at which point centrifugation was convenient to purifying and concentrate A β (1-42) from the cleavage mixture.

Non-cleaved fusion protein co-aggregated with A β (1-42) and required further purification by preparative RP-HPLC to remove. SUMO-A β (1-42) and traces of free SUMO eluted between 15 and 18 minutes, while A β (1-42) eluted with a broad profile peaking at 20 minutes (Fig. 3A). The broad elution profile of A β (1-42) is consistent with aggregation on the column, which is expected from the highly hydrophobic nature of the peptide. ESI-MS confirmed the mass of unlabeled, 15 N- and 13 C 15 N A β (1-42) to be 4514.53 Da, 4568.64 Da and 4764.23 Da (Fig. 3B, 3C), respectively, and only trace quantities of non-cleaved fusion protein remaining (Fig. 3C).

Biophysical characterization of A β (1-42)

Solution NMR on aqueous preparations was used to confirm the chemical and conformational purity of uniformly-labeled A β (1-42). At the high concentrations required, it is strictly necessary that pre-aggregated material are removed; otherwise seeded fibrillization would lead to rapid loss in signal. Ammonia pretreatment, followed by dissolution into sodium hydroxide (46) worked effectively for this purpose. Figure 4 displays a well-resolved HSQC spectrum of monomeric A β (1-42). Cross-peak positions are well-matched to previous spectra of either A β (1-40) or A β (1-42) with similar buffer composition and temperature (18, 30, 31, 47-

52). In addition, samples maintained at 5°C were stable for periods exceeding one week, which allowed confirmation of $^1\text{H}^{15}\text{N}$ HSQC assignments through a longer triple-resonance ^{15}N -edited HNCACB experiment. The absence of the His⁶ amide cross-peak in our HSQC is consistent with spectra reported by Williamson *et al.* (2006) for A β (1-40) (47), while our peak positions for residues Val³⁶ to Val⁴⁰ display relative downfield shifts, possibly explained by greater beta-sheet propensity in the C-terminus for A β (1-42) (18). Resonances for Ala² and Asp⁷ in HSQC spectra, overlapped with Ala³⁰ and Asp²³, respectively, were assigned directly by reference to Williamson *et al.* (2006), however, it should be noted that our experiments could not confirm this as neither the HN(i)/C α C β (i-1) or HN(i)/C α C β (i) correlation was observed in HNCACB spectra for these residues. In other studies, absence of His¹³ and His¹⁴, and deviations of Asp⁷, Asn²⁷ and Lys²⁸ amide cross-peaks positions, relative to our HSQC spectra also exist (18, 30, 31, 49), and may possibly be explained by differences in sample preparation (i.e. our inclusion of NaCl, and strength of ammonia pretreatment). Furthermore, the Met³⁵ chemical shift position suggests that A β (1-42) is in the reduced form (18), consistent with ESI-MS characterization (Fig. 3B, 3C).

Thioflavin T assays were used to characterize the aggregation kinetics of recombinant A β (1-42). Figure 5A displays a distinct lag phase, elongation phase and stationary phase over a 24-hour incubation period at 37°C for synthetic material, typical of A β aggregation (53). In contrast, recombinant peptide displayed negligible increases in ThT fluorescence, suggesting suppression of fibril formation at low concentration (10 μM). At significantly higher concentrations used for NMR (>200 μM), heating samples upwards of 5°C caused rapid loss in signal and visible development of turbidity, which is consistent with fibrillization. Circular dichroism spectra of used NMR sample (5 days old), but stored at no higher than 5°C and with no visible appearance of aggregation, showed evidence of some helical content based upon characteristic minima at 208 and 222 nm. However, the typical lineshape produce by the presence of α helix should lead to a *ca.* 2-fold greater positive band at 190 nm, which was not observed in Fig 5A. The low intensity may be explained by a high proportion of random coil content producing a strong negative band at 190 nm. Upon heating

from 5°C to 50°C, a two-state transition was observed with an isodichroic point at ca. 210 nm. A positive band at 195 nm and a negative band at 218 nm developed during the heating phase, typical of increasing content of β sheet structures. This is also consistent with the NMR data where increasing the temperature induced a loss of the NMR signal due to aggregation.

Discussion

Here we have utilized a SUMO-A β (1-42) fusion for the purpose of routinely producing milligram quantities of ^{15}N and $^{13}\text{C}^{15}\text{N}$ labeled A β (1-42) suitable for NMR studies. Similar to other fusion strategies based on GST, HEL, (NANP)₁₉, and MBP partners, which have previously been proven successful for expressing A β peptides [19-22], SUMO alleviated insolubility, could be enzymatically cleaved to release entirely native peptide (i.e. no N-Met) without any trace of N-terminal modification, and allowed single-step isolation from cell lysates, in our case from a polyhistidine tag and Ni-NTA affinity chromatography. Furthermore, SUMO does not rely upon tethering via linker sequences specific to proteases such as Factor Xa, EK or TEV, which are required in large quantities and have known instances of infidelity leading to N-terminal artifacts (30, 33). Instead, recognition intrinsic to the structure of SUMO allows SUMO protease to cleave the C-terminus with much greater fidelity and potency (33). For analogous advantages to SUMO, the ubiquitin (Ub)-fused Ub-A β (1-42) has also received interest, (54) with improvements in expression and overall yields of A β (1-42) realized for the double-fusions GroES-Ub-A β (1-42) (55) and trigger factor-Ub-A β (1-42) (56), but even under these improved circumstances, yields are only at comparable levels to our work despite the greater degree of complexity required.

The potential benefits of SUMO for expressing the notoriously difficult A β (1-42) has also been realized in past work by Satakarni and Curtis (32), which found expression of SUMO-A β (1-42), extrapolated from 25 mL scale, to exceed 200 mg/L of culture. Indeed, our values (~100 mg/L of culture) were considerably lower, which may in some part be

associated with the preparative (>1 L) scale of our work, our use of *E. coli* BL21(DE3) instead of an *E. coli* Rosetta (DE3) pLysS expression strain, or possibly differing methods of protein quantification (not explicitly disclosed in prior work (32)). Furthermore, it was realized in our work that significant challenges were associated with using SUMO-A β (1-42) for the eventual preparative-scale production of A β (1-42). Firstly, despite being considerably more soluble than A β (1-42), the fusion construct still localizes primarily in inclusion bodies (32). While this has commonly been observed for other fusion constructs (28, 30, 31, 55), requirements for dissolution into denaturing buffers is undesirable owing to risks of protein modifications (43) and losses in yields and time associated with refolding. Fortunately, SUMO-A β (1-42) could be refolded by on-resin buffer exchange, effectively averting days of dialysis. Secondly, and perhaps the most significant barrier to up-scaled application, is that even at the full published activity (33), a typical batch of 100 mg of SUMO-A β (1-42) would require ~15000 units of enzyme to process, which by current commercial suppliers would be a cost prohibitive quantity. Furthermore, the activity of Ulp1(403-621), which we expressed by a method adapted from Lee *et al.* (35), was found to be orders of magnitude less than theoretically expected (33), therefore, adding to already-burdensome enzyme requirements. In agreement with Satakarni and Curtis (32), DLS analysis suggested the presence of soluble aggregates, which could have been responsible for reduced enzyme activity and ~25% loss in overall yields of A β (1-42) due to non-cleaved fusion protein, albeit this was not an issue for the prior study. Instead, complete cleavage and activity was observed from their reactions in buffer containing 2 M urea and 37°C, which may have destabilized aggregate assemblies to some extent, but would have also introduced risks of carbamylation modifications from urea degradation. For our work, prolonged reactions at 1:1000 molar ratio of enzyme to substrate, at low temperature in native buffer, was an acceptable solution for reduced activity, allowing a single preparation (grown from 1 L of culture) of Ulp1(403-621) to be sufficient hundreds of preparative-scale cleavage reactions.

Overall yields of lyophilized A β (1-42) from our work exceeded 10 mg per liter of culture at either natural isotopic abundance with uniformly ¹⁵N or ¹³C¹⁵N labeling (see Table 1

for summary of yields and ESI-MS analysis). While these yields (of unlabeled peptide) could have been significantly improved by using higher-density growth media over LB (i.e. TB), doing so would have been misleading for the NMR spectroscopist given that similar yields would be unrealistic from culture media commonly used for isotope labeling – as exemplified by Long *et al.* in expressing a GST-A β ₄₀ fusion, in which a five-fold reduction in yield was observed between TB and M9 media (30). In contrast, our yields of uniformly labeled material from Neidhardt's minimal media were identical to that obtained from LB.

From ESI-MS analysis, A β (1-42) was confirmed to be entirely free of Met³⁵ oxidation or other PTMs, while solution NMR provided additional confidence that the final product obtained in a native unstructured state, and that chemical shifts were consistent with prior published work (18, 30, 31, 47-52). In addition, the peptide was remarkably stable throughout NMR acquisition, easily providing for at least one week of spectral acquisition despite having near-physiological concentrations of salt present, which have been noted to reduce sample lives to less than 24 hours (47). Furthermore, ThT assays provided further evidence that the recombinant peptide was suppressed from fibrillization relative to synthetic material, which is contrary to the conclusions made by Finder *et al.* that recombinant material aggregates faster as a result of being absent of the synthetic and racemic impurities inherent in SPSS (28). While the exact reasons for this discrepancy are unclear, trace quantities of non-cleaved fusion protein remaining from HPLC purification as result of broad elution profiles, evident from ESI-MS analysis, but not observable in NMR spectra, may have had some chaperoning effect. Overall, utilization of SUMO fusion methodology has proven applicable as a cost-effective means for the large-scale biosynthetic production of isotopically-enriched A β (1-42), and possibly amyloidogenic peptides in general.

Acknowledgements

The authors would like to sincerely thank Dr. Nick Williamson, Paul O'Donnell and Michael Leeming for discussions regarding ESI-MS acquisition and analysis, John Karas for advice

on HPLC purification, and Professor Anthony Wedd and Dr. Zhiguang Xiao for allowing access to equipment required for cell-culture work.

Funding

J. Gehman was partially funded by ARC Future Fellowship FT0991558 for this work. Circular Dichroism and Dynamic Light Scattering instruments were funded by a LIEF grant LE120100186 to G. Bryant (RMIT) and J. Gehman. D. Weber is thankful for an Australian Postgraduate Award PhD scholarship and Dowd Foundation Postgraduate Research Scholarship for Neuroscience.

465 **References**

- 466 1. Sisodia, S. S. (1992) β -Amyloid precursor protein cleavage by a membrane-
467 bound protease. *Proceedings of the National Academy of Sciences of the United*
468 *States of America* 89:6075-6079
- 469 2. Selkoe, D. J. (2012) Preventing alzheimer's disease. *Science* 337:1488-1492
- 470 3. Watt, A. D., Villemagne, V. L., and Barnham, K. J. (2012) Metals, membranes, and
471 amyloid- β oligomers: Key pieces in the Alzheimer's disease puzzle? (Perry, G.,
472 Zhu, X., Smith, M. A., Sorensen, A., and Avila, J., eds) 3:283-293
- 473 4. Butterfield, D. A., and Lauderback, C. M. (2002) Lipid peroxidation and protein
474 oxidation in Alzheimer's disease brain: Potential causes and consequences
475 involving amyloid β -peptide-associated free radical oxidative stress. *Free*
476 *Radical Biology and Medicine* 32:1050-1060
- 477 5. Barnham, K. J., Haeflner, F., Ciccotosto, G. D., Curtain, C. C., Tew, D., Mavros, C.,
478 Beyreuther, K., Carrington, D., Masters, C. L., Cherny, R. A., Cappai, R., and Bush, A.
479 I. (2004) Tyrosine gated electron transfer is key to the toxic mechanism of
480 Alzheimer's disease β -amyloid. *FASEB Journal* 18:1427-1429
- 481 6. Barnham, K. J., Ciccotosto, G. D., Tickler, A. K., Ali, F. E., Smith, D. G., Williamson, N.
482 A., Lam, Y. H., Carrington, D., Tew, D., Kocak, G., Volitakis, I., Separovic, F., Barrow,
483 C. J., Wade, J. D., Masters, C. L., Cherny, R. A., Curtain, C. C., Bush, A. I., and Cappai,
484 R. (2003) Neurotoxic, Redox-competent Alzheimer's β -Amyloid Is Released from
485 Lipid Membrane by Methionine Oxidation. *Journal of Biological Chemistry*
486 278:42959-42965
- 487 7. Weber, D. K., Gehman, J. D., Separovic, F., and Sani, M. A. (2012) Copper
488 modulation of amyloid beta 42 interactions with model membranes. *Australian*
489 *Journal of Chemistry* 65:472-479
- 490 8. Gehman, J. D., O'Brien, C. C., Shabanpoor, F., Wade, J. D., and Separovic, F. (2008)
491 Metal effects on the membrane interactions of amyloid- β peptides. *European*
492 *Biophysics Journal* 37:333-344
- 493 9. Lau, T. L., Gehman, J. D., Wade, J. D., Masters, C. L., Barnham, K. J., and Separovic, F.
494 (2007) Cholesterol and Clioquinol modulation of A β (1-42) interaction with
495 phospholipid bilayers and metals. *Biochimica et Biophysica Acta - Biomembranes*
496 1768:3135-3144
- 497 10. Lau, T. L., Gehman, J. D., Wade, J. D., Perez, K., Masters, C. L., Barnham, K. J., and
498 Separovic, F. (2007) Membrane interactions and the effect of metal ions of the
499 amyloidogenic fragment A β (25-35) in comparison to A β (1-42). *Biochimica et*
500 *Biophysica Acta - Biomembranes* 1768:2400-2408
- 501 11. Sciacca, M. F. M., Kotler, S. A., Brender, J. R., Chen, J., Lee, D. K., and Ramamoorthy,
502 A. (2012) Two-step mechanism of membrane disruption by A β through
503 membrane fragmentation and pore formation. *Biophysical Journal* 103:702-710
- 504 12. Sticht, H., Bayer, P., Willbold, D., Dames, S., Hilbich, C., Beyreuther, K., Frank, R. W.,
505 and Rosch, P. (1995) Structure of amyloid A4-(1-40)-peptide of Alzheimer's
506 disease. *European Journal of Biochemistry* 233:293-298
- 507 13. Coles, M., Bicknell, W., Watson, R. A., Fairlie, D. P., and Craik, D. J. (1998) Solution
508 structure of amyloid β -peptide(1-40) in a water-micelle environment. Is the
509 membrane-spanning domain where we think it is? *Biochemistry* 37:11064-
510 11077

14. Watson, A. A., Fairlie, D. P., and Craik, D. J. (1998) Solution structure of methionine-oxidized amyloid β -peptide (1-40). Does oxidation affect conformational switching? *Biochemistry* 37:12700-12706
15. Crescenzi, O., Tomaselli, S., Guerrini, R., Salvadori, S., D'Ursi, A. M., Temussi, P. A., and Picone, D. (2002) Solution structure of the Alzheimer amyloid β -peptide (1-42) in an apolar microenvironment: Similarity with a virus fusion domain. *European Journal of Biochemistry* 269:5642-5648
16. Tomaselli, S., Esposito, V., Vangone, P., Van Nuland, N. A. J., Bonvin, A. M. J. J., Guerrini, R., Tancredi, T., Temussi, P. A., and Picone, D. (2006) The α -to- β conformational transition of Alzheimer's A β -(1-42) peptide in aqueous media is reversible: A step by step conformational analysis suggests the location of β conformation seeding. *ChemBioChem* 7:257-267
17. Vivekanandan, S., Brender, J. R., Lee, S. Y., and Ramamoorthy, A. (2011) A partially folded structure of amyloid-beta(1-40) in an aqueous environment. *Biochemical and Biophysical Research Communications* 411:312-316
18. Hou, L., Shao, H., Zhang, Y., Li, H., Menon, N. K., Neuhaus, E. B., Brewer, J. M., Byeon, I. J. L., Ray, D. G., Vitek, M. P., Iwashita, T., Makula, R. A., Przybyla, A. B., and Zagorski, M. G. (2004) Solution NMR Studies of the A β (1-40) and A β (1-42) Peptides Establish that the Met35 Oxidation State Affects the Mechanism of Amyloid Formation. *Journal of the American Chemical Society* 126:1992-2005
19. Lührs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Döbeli, H., Schubert, D., and Riek, R. (2005) 3D structure of Alzheimer's amyloid- β (1-42) fibrils. *Proceedings of the National Academy of Sciences of the United States of America* 102:17342-17347
20. Petkova, A. T., Ishii, Y., Balbach, J. J., Antzutkin, O. N., Leapman, R. D., Delaglio, F., and Tycko, R. (2002) A structural model for Alzheimer's β -amyloid fibrils based on experimental constraints from solid state NMR. *Proceedings of the National Academy of Sciences of the United States of America* 99:16742-16747
21. Petkova, A. T., Yau, W. M., and Tycko, R. (2006) Experimental constraints on quaternary structure in Alzheimer's β -amyloid fibrils. *Biochemistry* 45:498-512
22. Paravastu, A. K., Leapman, R. D., Yau, W. M., and Tycko, R. (2008) Molecular structural basis for polymorphism in Alzheimer's β -amyloid fibrils. *Proceedings of the National Academy of Sciences of the United States of America* 105:18349-18354
23. Lu, J. X., Qiang, W., Yau, W. M., Schwieters, C. D., Meredith, S. C., and Tycko, R. (2013) Molecular structure of β -amyloid fibrils in alzheimer's disease brain tissue. *Cell* 154:1257-1268
24. Sgourakis, N. G., Merced-Serrano, M., Boutsidis, C., Drineas, P., Du, Z., Wang, C., and Garcia, A. E. (2011) Atomic-level characterization of the ensemble of the A β (1-42) monomer in water using unbiased molecular dynamics simulations and spectral algorithms. *Journal of Molecular Biology* 405:570-583
25. Rosenman, D. J., Connors, C. R., Chen, W., Wang, C., and García, A. E. (2013) A β monomers transiently sample oligomer and fibril-like configurations: Ensemble characterization using a combined MD/NMR approach. *Journal of Molecular Biology* 425:3338-3359
26. Ball, K. A., Phillips, A. H., Wemmer, D. E., and Head-Gordon, T. (2013) Differences in β -strand populations of monomeric A β 40 and A β 42. *Biophysical Journal* 104:2714-2724

27. Mehta, A. K., Rosen, R. F., Childers, W. S., Gehman, J. D., Walker, L. C., and Lynn, D. G. (2013) Context dependence of protein misfolding and structural strains in neurodegenerative diseases. *Biopolymers* 100:722-730
28. Finder, V. H., Vodopivec, I., Nitsch, R. M., and Glockshuber, R. (2010) The Recombinant Amyloid- β Peptide A β 1-42 Aggregates Faster and Is More Neurotoxic than Synthetic A β 1-42. *Journal of Molecular Biology* 396:9-18
29. Hortschansky, P., Schroeckh, V., Christopeit, T., Zandomenighi, G., and Fändrich, M. (2005) The aggregation kinetics of Alzheimer's β -amyloid peptide is controlled by stochastic nucleation. *Protein Science* 14:1753-1759
30. Long, F., Cho, W., and Ishii, Y. (2011) Expression and purification of 15N- and 13C-isotope labeled 40-residue human Alzheimer's β -amyloid peptide for NMR-based structural analysis. *Protein Expression and Purification* 79:16-24
31. Nagata-Uchiyama, M., Yaguchi, M., Hirano, Y., and Ueda, T. (2007) Expression and purification of uniformly 15N-labeled amyloid β peptide 1-40 in *Escherichia coli*. *Protein and Peptide Letters* 14:788-792
32. Satakarni, M., and Curtis, R. (2011) Production of recombinant peptides as fusions with SUMO. *Protein Expression and Purification* 78:113-119
33. Malakhov, M. P., Mattern, M. R., Malakhova, O. A., Drinker, M., Weeks, S. D., and Butt, T. R. (2004) SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. *Journal of Structural and Functional Genomics* 5:75-86
34. Walsh, D. M., Thulin, E., Minogue, A. M., Gustavsson, N., Pang, E., Teplow, D. B., and Linse, S. (2009) A facile method for expression and purification of the Alzheimer's disease-associated amyloid β -peptide. *FEBS Journal* 276:1266-1281
35. Lee, C. D., Sun, H. C., Hu, S. M., Chiu, C. F., Homhuan, A., Liang, S. M., Leng, C. H., and Wang, T. F. (2008) An improved SUMO fusion protein system for effective production of native proteins. *Protein Science* 17:1241-1248
36. Neidhardt, F. C., Bloch, P. L., and Smith, D. F. (1974) Culture medium for enterobacteria. *Journal of Bacteriology* 119:736-747
37. Gehman, J. D., Cocco, M. J., and Grindley, N. D. F. (2008) Chemical shift mapping of γ δ resolvase dimer and activated tetramer: Mechanistic implications for DNA strand exchange. *Biochimica et Biophysica Acta - Proteins and Proteomics* 1784:2086-2092
38. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. *Analytical Biochemistry* 72:248-254
39. Kuipers, B. J. H., and Gruppen, H. (2007) Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. *Journal of Agricultural and Food Chemistry* 55:5445-5451
40. Wishart, D. S., Bigam, C. G., Yao, J., Abildgaard, F., Dyson, H. J., Oldfield, E., Markley, J. L., and Sykes, B. D. (1995) 1H, 13C and 15N chemical shift referencing in biomolecular NMR. *Journal of Biomolecular NMR* 6:135-140
41. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRPipe: A multidimensional spectral processing system based on UNIX pipes. *Journal of Biomolecular NMR* 6:277-293
42. Vranken, W. F., Boucher, W., Stevens, T. J., Fogh, R. H., Pajon, A., Llinas, M., Ulrich, E. L., Markley, J. L., Ionides, J., and Laue, E. D. (2005) The CCPN data model for

- NMR spectroscopy: Development of a software pipeline. *Proteins: Structure, Function and Genetics* 59:687-696
43. Kollipara, L., and Zahedi, R. P. (2013) Protein carbamylation: In vivo modification or in vitro artefact? *Proteomics* 13:941-944
 44. Frottin, F., Martinez, A., Peynot, P., Mitra, S., Holz, R. C., Giglione, C., and Meinel, T. (2006) The proteomics of N-terminal methionine cleavage. *Molecular and Cellular Proteomics* 5:2336-2349
 45. Geoghegan, K. F., Dixon, H. B. F., Rosner, P. J., Hoth, L. R., Lanzetti, A. J., Borzilleri, K. A., Marr, E. S., Pezzullo, L. H., Martin, L. B., Lemotte, P. K., McColl, A. S., Kamath, A. V., and Stroh, J. G. (1999) Spontaneous α -N-6-phosphogluconoylation of a 'His tag' in *Escherichia coli*: The cause of extra mass of 258 or 178 Da in fusion proteins. *Analytical Biochemistry* 267:169-184
 46. Ryan, T. M., Caine, J., Mertens, H. D. T., Kirby, N., Nigro, J., Breheney, K., Waddington, L. J., Streltsov, V. A., Curtain, C., Masters, C. L., and Roberts, B. R. (2013) Ammonium hydroxide treatment of A β produces an aggregate free solution suitable for biophysical and cell culture characterization. *PeerJ* 1, e73
 47. Williamson, M. P., Suzuki, Y., Bourne, N. T., and Asakura, T. (2006) Binding of amyloid β -peptide to ganglioside micelles is dependent on histidine-13. *Biochemical Journal* 397:483-490
 48. Yan, Y., McCallum, S. A., and Wang, C. (2008) M35 oxidation induces A β 40-like structural and dynamical changes in A β 42. *Journal of the American Chemical Society* 130:5394-5395
 49. Danielsson, J., Andersson, A., Jarvet, J., and Gräslund, A. (2006) ¹⁵N relaxation study of the amyloid β -peptide: Structural propensities and persistence length. *Magnetic Resonance in Chemistry* 44:S114-S121
 50. Broersen, K., Jonckheere, W., Rozenski, J., Vandersteen, A., Pauwels, K., Pastore, A., Rousseau, F., and Schymkowitz, J. (2011) A standardized and biocompatible preparation of aggregate-free amyloid beta peptide for biophysical and biological studies of Alzheimers disease. *Protein Engineering, Design and Selection* 24:743-750
 51. Rezaei-Ghaleh, N., Andreetto, E., Yan, L. M., Kapurniotu, A., and Zweckstetter, M. (2011) Interaction between amyloid beta peptide and an aggregation blocker peptide mimicking islet amyloid polypeptide. *PloS one* 6
 52. Ghalebani, L., Wahlström, A., Danielsson, J., Wärmländer, S. K. T. S., and Gräslund, A. (2012) PH-dependence of the specific binding of Cu(II) and Zn(II) ions to the amyloid- β peptide. *Biochemical and Biophysical Research Communications* 421:554-560
 53. Sani, M. A., Gehman, J. D., and Separovic, F. (2011) Lipid matrix plays a role in A β fibril kinetics and morphology. *FEBS Letters* 585:749-754
 54. Lee, E. K., Hwang, J. H., Shin, D. Y., Kim, D. I., and Yoo, Y. J. (2005) Production of recombinant amyloid- β peptide 42 as an ubiquitin extension. *Protein Expression and Purification* 40:183-189
 55. Shahnawaz, M., Thapa, A., and Park, I. S. (2007) Stable activity of a deubiquitylating enzyme (Usp2-cc) in the presence of high concentrations of urea and its application to purify aggregation-prone peptides. *Biochemical and Biophysical Research Communications* 359:801-805
 56. Thapa, A., Shahnawaz, M., Karki, P., Dahal, G. R., Sharoar, M. G., Shin, S. Y., Lee, J. S., Cho, B., and Park, I. S. (2008) Purification of inclusion body-forming peptides and

656 proteins in soluble form by fusion to Escherichia coli thermostable proteins.
657 BioTechniques 44:787-796
658

Figure 1: PCR scheme for synthesizing the A β (1-42) gene. The modular approach and DNA sequence, codon-optimized for *E. coli*, was identical to that described by Walsh *et al.* (34). The reaction consisted of MyTaq Red Mix, sA β a (600 nM), aA β 42d (600 nM), sA β b (40 nM) and aA β c (40 nM), and underwent 2 cycles of 94°C (15 sec) and 35°C (45 sec); 2 cycles of 94°C (15 sec), 62°C (15 sec) and 64°C (30 sec); and a further 25 cycles of 94°C (15 sec), 66°C (15 sec) and 68°C (15 sec). XbaI and BsaI restriction sites, i.e. if T/A cloning vectors are not used, were then added by a second reaction using a one-tenth dilution of the prior reaction and primers sA β fwd (600 nM) and sA β rev (600 nM), then 2 cycles of 94°C (15 sec), 51°C (15 sec) and 52°C (30 sec); and 25 cycles of 94°C (15 sec), 66°C (15 sec) and 68°C (15 sec).

Figure 2: (A) Growth comparison of *E. coli* cultures expressing SUMO-A β (1-42) from either LB media or Neidhardt's minimal media used for uniform labeling. (B) Maximum entropy deconvolution of an ESI-MS spectrum of SUMO-A β (1-42) at natural isotope abundance. Peaks identified at 16953 and 17033 likely correspond to α -N-gluconoyl and α -N-6-phosphogluconoyl PTMs, respectively. (C) 15% SDS-PAGE gel of *E. coli* pre- and post-induction of SUMO-A β (1-42) expression by IPTG (hours 1-4, lanes 2-6); and Ni-NTA purified SUMO-A β (1-42), non-cleaved (NC, lane 7), and cleaved at 1:1000 molar ratio of SUMO protease to fusion protein after 3 days incubation at 4°C in native elution buffer (C, lane 8). (D) Cleavage of 10 μ M SUMO-A β (1-42) by Ulp1 over 1 hour at 4°C in buffer (50 mM sodium phosphate, 100 mM NaCl, pH 8.0). Molar ratios of SUMO-A β (1-42) to protease are displayed below each lane. (E) Size-intensity distribution, proportional to the sixth power of hydrodynamic radius, from dynamic light scattering of SUMO-A β (1-42) in elution buffer (50 mM sodium phosphate, 300 mM NaCl, 250 mM Imidazole, pH 8.0, 4°C). Measurements were made using a Malvern Zetasizer Nano ZS in 173° backscatter mode and analyzed by manufacturer's software.

Figure 3: (A) Preparative RP-HPLC elution profile of A β (1-42) detected by UV-absorbance (solid line) and showing acetonitrile concentration (dashed line). Peaks are identified corresponding to free SUMO and non-cleaved fusion protein impurities (*) and A β (1-42) (†). (B) Raw and (C) maximum entropy deconvolution of ESI-MS spectrum of HPLC-purified $^{13}C^{15}N$ A β (1-42). A peak observed at +17.5 Da is consistent with water adducts and not oxidation of Met³⁵

Figure 4: 500 MHz HSQC spectrum of 380 μM $^{13}\text{C}/^{15}\text{N}$ A β (1-42) in buffer (15 mM sodium phosphate, 55 mM NaCl, pH 7.4) at 5 $^{\circ}\text{C}$. Spectra were recorded using the standard Bruker hsqcetf3gpsi pulse sequence with 10.97 ppm spectral width and 2048 points in the ^1H dimension, and 40 ppm spectral width and 256 points in the ^{15}N dimension. Processing was performed using NMRPipe (41) with solvent filtering, sine-bell apodization with maximum shifted to 50% acquisition time, zero filling for both dimensions and forward-back linear prediction for the indirect ^{15}N dimension.

Figure 5: (A) ThT aggregation curve of synthetic (squares) and recombinant (triangles) A β (1-42). Samples consisted of 10 μ M peptide and 20 μ M ThT in buffer (30 mM sodium phosphate, 100 mM NaCl, pH 7.4). Measurements were made at 37°C every 10 minutes. (B) CD spectra of 220 μ M $^{13}\text{C}^{15}\text{N}$ A β (1-42) after 5 days of NMR measurements at 5°C. Temperature was incremented to 50°C in steps of 5°C with 5 minutes equilibration prior to each scan.

Table 1: Summary of yields and ESI-MS confirmation of proteins and peptides produced from this study.

	Experimental	Theoretical	Enrichment	Yield
	M.W.	M.W.		(mg/L of culture)
	Da	Da		
Ulp1	27250.24	27249.96	-	60
SUMO-A β (1-42)	16774.73	16775.03 [†]	-	96
¹⁵ N SUMO-A β (1-42)	16985.16	16987.16 [†]	¹⁵ N (99%)	96
¹³ C ¹⁵ N SUMO-A β (1-42)	17690.91	17717.76 [†]	¹⁵ N (99%), ¹³ C (97%)	181 [‡]
A β (1-42)	4514.53	4514.08	-	13
¹⁵ N A β (1-42)	4568.64	4568.68	¹⁵ N (99%)	12
¹³ C ¹⁵ N A β (1-42)	4764.23	4770.19	¹⁵ N (99%), ¹³ C (97%)	22 [‡]

[†] Theoretical molecular weights take the loss of N-terminal methionine into account. Additional peaks at 178 Da (Unlabeled, ¹⁵N-labeled), 183 Da (¹³C-labeled), and 258 Da (Unlabeled, ¹⁵N-labeled) may appear in ESI-MS spectra and are likely N-terminal α N-gluconoyl and α N-6-phosphogluconoyl PTMs.

[‡] Reported yield neglects the volume of culture used to grow cell mass under natural ¹³C abundance.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Weber, DK;Sani, M-A;Gehman, JD

Title:

A routine method for cloning, expressing and purifying A beta(1-42) for structural NMR studies

Date:

2014-10-01

Citation:

Weber, D. K., Sani, M. -A. & Gehman, J. D. (2014). A routine method for cloning, expressing and purifying A beta(1-42) for structural NMR studies. AMINO ACIDS, 46 (10), pp.2415-2426. <https://doi.org/10.1007/s00726-014-1796-x>.

Persistent Link:

<http://hdl.handle.net/11343/283290>